Citius Pharmaceuticals, Inc.
CTXR
$0.968
-$0.021-2.12%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 31.28M | 30.09M | 29.20M | 26.23M | 24.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.69M | 42.00M | 41.07M | 39.11M | 38.82M |
| Operating Income | -42.69M | -42.00M | -41.07M | -39.11M | -38.82M |
| Income Before Tax | -39.78M | -38.85M | -37.72M | -35.62M | -37.60M |
| Income Tax Expenses | 696.20K | 576.00K | 576.00K | 576.00K | 576.00K |
| Earnings from Continuing Operations | -40.48 | -39.43 | -38.29 | -36.20 | -38.18 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 800.00K | 287.00K | -- | -- | -- |
| Net Income | -39.68M | -39.14M | -38.29M | -36.20M | -38.18M |
| EBIT | -42.69M | -42.00M | -41.07M | -39.11M | -38.82M |
| EBITDA | -42.69M | -41.99M | -41.07M | -39.11M | -38.82M |
| EPS Basic | -5.80 | -5.95 | -6.11 | -5.92 | -6.37 |
| Normalized Basic EPS | -3.67 | -3.80 | -3.85 | -3.76 | -3.81 |
| EPS Diluted | -5.92 | -6.06 | -6.15 | -6.08 | -6.54 |
| Normalized Diluted EPS | -3.67 | -3.80 | -3.85 | -3.76 | -3.81 |
| Average Basic Shares Outstanding | 28.04M | 26.91M | 26.03M | 25.23M | 24.72M |
| Average Diluted Shares Outstanding | 28.04M | 26.91M | 26.03M | 25.23M | 24.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |